Back to results
US 2018/0002416 A1Published application
Early marker of proteinuria in patients treated with an anti-vegf treatment
AssigneeMayo Foundation for Medical Education and Research
InventorVesna D. Garovic
Life of this patent
Estimating the term…
Abstract
This document provides methods and materials related to determining whether or not a human receiving a therapy (e.g., an anti-VEGF therapy such as a bevacizumab therapy) has developed or is at risk for developing proteinuria. For example, methods and materials for detecting urinary podocytes to determine whether or not a human receiving anti-VEGF therapy has or is at risk for developing proteinuria or kidney injury are provided.
Claims1
A method for assessing a human who has received an anti-VEGF therapy for a risk of developing proteinuria, said method comprising:
- determining whether or not a urine sample from a human receiving anti-VEGF therapy contains one or more urinary podocytes or evidence of one or more urinary podocytes, wherein the presence of said one or more urinary podocytes or said evidence indicates that said human is at risk for developing proteinuria.
Dependencies are inferred from the claim text.